A share price of Immunovant Inc [IMVT] is currently trading at $26.42, up 6.49%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMVT shares have gain 15.67% over the last week, with a monthly amount glided 12.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on October 14, 2025, when Truist initiated its Hold rating and assigned the stock a price target of $16. On March 03, 2025, Jefferies initiated with a Hold rating and assigned a price target of $20 on the stock. Wolfe Research downgraded its rating to a Peer Perform. Oppenheimer reiterated an Outperform rating for this stock on October 09, 2024, and upped its price target to $53. In a note dated March 28, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $50 on this stock.
Immunovant Inc experienced fluctuations in its stock price throughout the past year between $12.72 and $29.10. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $26.42 at the most recent close of the market. An investor can expect a potential drop of -39.44% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is -0.85 and Total Capital is -0.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.09 points at the first support level, and at 23.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.13, and for the 2nd resistance point, it is at 27.83.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunovant Inc [NASDAQ:IMVT] is 9.07. Also, the Quick Ratio is 9.07, while the Cash Ratio stands at 8.25.
Transactions by insiders
Recent insider trading involved Roivant Sciences Ltd., Director, that happened on Dec 12 ’25 when 16.67 million shares were purchased. Director, Fromkin Andrew J. completed a deal on Dec 01 ’25 to sell 22249.0 shares. Meanwhile, Director Hughes Douglas J. sold 15000.0 shares on Dec 01 ’25.
